Results 71 to 80 of about 427,029 (392)

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

Haematologica, 2012
Background Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia.
Ion Cristóbal, Laura Garcia-Orti, Cristina Cirauqui, Xabier Cortes-Lavaud, María A. García-Sánchez, María J. Calasanz, María D. Odero   +6 more
doaj   +1 more source

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma, Baron, Boztug, Boztug, Bredeson, Burroughs, Carreras, Casper, Casper, Cieri, Copelan, Dalle, Danylesko, Fichtner, Galaup, Glowka, Gupta, Gyurkocza, Kroger, Kroger, Majhail, Meinhardt, Munkelt, Nagler, Nagler, Palmer, Pel, Richardson, Rizzo, Savani, Savani, Scheulen, Schmidmaier, Schmitt, Sengsayadeth, Sengsayadeth, Shimoni, Shimoni, Slatter, ten Brink, Wachowiak, Williams   +41 more
core   +1 more source

Chronic myeloid leukemia stem cells

Leukemia, 2019
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC).
M. Houshmand, G. Simonetti, P. Circosta, Valentina Gaidano, A. Cignetti, G. Martinelli, G. Saglio, R. Gale   +7 more
semanticscholar   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells

Tumor Biology, 2017
Chronic myeloid leukemia is characterized by the presence of the reciprocal translocation t(9;22) and the BCR/ABL oncogene. The BCR/ABL oncogene activates multiple signaling pathways and involves the dysregulation of oncogenes during the progression of ...
Jia-Hua Zhang, Yan-Li He, Rui Zhu, Wen Du, Jun-Hua Xiao   +4 more
doaj   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]

, 2005
Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR, DEL GIUDICE, ILARIA, DIVERIO D, FOA, Roberto, GIONA, Fiorina, MANDELLI, Franco, MOLETI ML, TESTI, Anna Maria   +7 more
core   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

Tumor Biology, 2017
Platelet-derived growth factor receptor has been implicated in many malignant and non-malignant diseases. Platelet-derived growth factor receptor-α is a tyrosine kinase and a side target for imatinib, a revolutionary drug for the treatment of chronic ...
Sameer Ahmad Guru, Rashid Mir, Musadiq Bhat, Imtiyaz Najar, Mariyam Zuberi, Mamta Sumi, Mirza Masroor, Naresh Gupta, Alpana Saxena   +8 more
doaj   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

Haematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki   +16 more
doaj   +1 more source